Experimental Drug Improved FUS-ALS Patient Survival
A new treatment successfully targeted the genetic cause of this rare condition in a late-stage clinical trial.
Updated on Sept. 22, 2026 in Alzheimer’s
Live Poll
Should pharmaceutical companies accelerate the development of experimental drugs for rare, fatal conditions?
An experimental drug called ulefnersen has met its primary endpoint in a late-stage trial for patients with FUS-ALS, showing improvements in patient function and survival. The treatment is the first to specifically target the genetic cause of this rare disease.
Why it matters
FUS-ALS causes progressive nerve cell damage and muscle weakness, and there are currently no approved treatments addressing its underlying genetic root. This development offers a potential new avenue for patients who previously had no targeted therapeutic options.
In a late-stage trial, the experimental drug ulefnersen demonstrated improved survival and function compared to a placebo in patients with FUS-ALS. The study also observed a reduction in biological markers associated with nerve cell damage.
The players
Otsuka Pharmaceutical
A global pharmaceutical company focused on the development of treatments for neurological and psychiatric conditions.
Ionis Pharmaceuticals
A biotechnology company specializing in RNA-targeted therapies for rare and severe diseases.
US FDA
The federal agency responsible for regulating pharmaceuticals and public health in the United States.
The details
Ulefnersen works by reducing the production of the FUS protein, which is linked to the genetic cause of the disease. By lowering these protein levels, the drug aims to mitigate the progressive nerve cell damage and muscle weakness characteristic of FUS-ALS. In the study, the majority of side effects reported were classified as mild or moderate.
Timeline
September 22, 2026: The companies reported positive trial results.
Health Landscape
This development represents a departure from the traditional approach of managing ALS symptoms toward therapies that target specific genetic drivers. It follows the growing trend of gene-silencing research aimed at addressing the underlying biological causes of neurodegenerative disorders.
For patients with FUS-ALS, the early access program allows physicians to request access to the drug before broad regulatory approval. It is worth discussing this treatment option and the possibility of participating in local access programs with a neurologist.
The takeaway
Ulefnersen represents a significant milestone by targeting the genetic root of FUS-ALS, a condition that previously lacked specialized treatments. Patients and their caregivers should monitor updates from global health authorities regarding the potential for accelerated approval.
Further reading
Learn more about the latest research in the field of Alzheimer’s.
Live Poll
Should pharmaceutical companies accelerate the development of experimental drugs for rare, fatal conditions?
